Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

AB SCIEX Announces In Vitro Diagnostic Devices CE Marked for Europe

Published: Tuesday, May 21, 2013
Last Updated: Tuesday, May 21, 2013
Bookmark and Share
AB SCIEX launches the 3200MD CE-IVDD series for general in vitro diagnostic use in Europe.

Meeting regulatory requirements to obtain the CE-IVDD mark for the new AB SCIEX API 3200MD™ and 3200MD QTRAP® LC/MS/MS systems* will provide European hospitals and clinical diagnostic laboratories the confidence to use these mass spectrometry-based systems to improve the quality of results in clinical analysis while reducing costs.  

“We are focused on meeting the medical, technological and compliance needs of clinical diagnostic laboratories and hospitals,” said Rainer Blair, President of AB SCIEX.  “The use of LC/MS/MS technology for clinical diagnostics has already been proven to deliver faster, more accurate results at lower cost compared to existing technologies.  Now, we are bringing these benefits to Europe in a way that will simplify and accelerate adoption of this powerful technology.”

The announcement, made at the EuroMedLab conference in Milan, Italy follows on the heels of the company’s announcement of the family of 3200MD systems earlier this year.  The 3200MD series is the company’s first of a family of in vitro diagnostic devices.  The intended use of these devices is to identify inorganic or organic compounds in human specimens for clinical use.  

AB SCIEX plans to continue to roll out regulatory-compliant systems around the world in the future.  With these IVD devices, the company is delivering on its strategy to expand the use of its technology in clinical diagnostics, which is widely deemed a new frontier for mass spectrometry.

AB SCIEX has a two-decade track record of success in the clinical research (RUO) market.  The company has excelled at advancing and simplifying LC/MS/MS technology, so it is easier for laboratories to adopt and utilize for routine analysis.  The robustness and ease of use of the 3200 product line makes it a preferred instrument for research laboratories of all sizes.  Now applying its expertise and experience to the IVD market, AB SCIEX is also expanding its service offerings to provide enhanced service and support specifically for clinical diagnostics.  

The AB SCIEX API 3200MD™ and 3200MD QTRAP® LC/MS/MS systems are expected to ship in Europe by     mid-June.

*Not available in every country.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

AB SCIEX Wins New Product Innovation Award in Asia Pacific
The award recognizes the company’s continued innovation in the mass spectrometry industry and a number of new products introduced into the market in recent years.
Thursday, October 30, 2014
AB SCIEX Receives Frost & Sullivan Award
AB SCIEX has been awarded the 2013 Global Market Share Leadership Award for Mass Spectrometry from Frost & Sullivan.
Thursday, September 12, 2013
AB SCIEX Achieves ISO 13485 Certification for Manufacturing of LC/MS Systems
This ISO certification is often considered a first step toward complying with European regulatory requirements for a device to be cleared for use in the clinic.
Monday, February 27, 2012
Scientific News
What do Banana Peels and Human Skin Have in Common?
Human skin and banana peels have something in common: they produce the same enzyme when attacked. By studying fruit, researchers have come up with an accurate method for diagnosing the stages of this form of skin cancer.
Biomarker for Recurring HPV-Linked Oropharyngeal Cancers
A look-back analysis of HPV infection antibodies in patients treated for oropharyngeal (mouth and throat) cancers linked to HPV infection suggests at least one of the antibodies could be useful in identifying those at risk for a recurrence of the cancer, say scientists at the Johns Hopkins University.
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Genomic Signature Shared by Five Types of Cancer
National Institutes of Health researchers have identified a striking signature in tumor DNA that occurs in five different types of cancer.
Crowdfunding the Fight Against Cancer
From budding social causes to groundbreaking businesses to the next big band, crowdfunding has helped connect countless worthy projects with like-minded people willing to support their efforts, even in small ways. But could crowdfunding help fight cancer?
"Gene Fusion" Drives Childhood Brain Cancers
Study co-led by Penn scientists highlights potential targets for future cancer therapies.
Head Injury Patients Develop Brain Clumps Associated with Alzheimer’s Disease
Scientists have revealed that protein clumps associated with Alzheimer's disease are also found in the brains of people who have had a head injury.
New Way to Identify Brain Tumor Aggressiveness
Looking at a brain tumor’s epigenetic signature may help guide therapy.
OncoCyte, The Wistar Institute Enter Global Licensing Agreement
Exclusive rights to commercialize biomarker assay follows years of positive collaboration on lung cancer diagnostic test.
Easier Diagnosis for Fungal Infection of the Lungs
A new clinical imaging method developed in collaboration with a University of Exeter academic may enable doctors to tackle one of the main killers of patients with weakened immune systems sooner and more effectively.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!